The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

endobetix.com

Stage

Other Investors | Alive

About Endobetix

Endobetix is developing a minimally invasive, nonsurgical implant to treat T2D and obesity that mimics the hormonal benefits offered by bariatric surgery.

Endobetix Headquarter Location

17 Tchelet Street

Misgav, 20174,

Israel

+972-72-260-7000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Endobetix Patents

Endobetix has filed 3 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/20/2011

12/1/2015

Substituted amphetamines, Obesity, CB1 receptor antagonists, Bariatrics, Cannabinoids

Grant

Application Date

7/20/2011

Grant Date

12/1/2015

Title

Related Topics

Substituted amphetamines, Obesity, CB1 receptor antagonists, Bariatrics, Cannabinoids

Status

Grant

Latest Endobetix News

Endobetix is a Finalist for the 2015 Red Herring Top 100 Europe Award

Apr 20, 2015

Red Herring Top 100 Europe Finalist MISGAV, Israel, April 20, 2015 /PRNewswire/ -- Endobetix Ltd., a developer of a minimally invasive, nonsurgical implant for the treatment of type 2 diabetes and obesity and a portfolio company of The Trendlines Group , announced today it has been selected as a finalist for Red Herring's Top 100 Europe award, a prestigious list honoring the year's most promising private technology ventures from the European business region. (Logo: http://photos.prnewswire.com/prnh/20150420/740132-b ) The Red Herring editorial team selected the most innovative companies from a pool of hundreds from across Europe. The nominees are evaluated on 20 main quantitative and qualitative criteria: they include disruptive impact, market footprint, proof of concept, financial performance, technology innovation, social value, quality of management, execution of strategy, and integration into their respective industries. This unique assessment of potential is complemented by a review of the actual track record and standing of a company, which allows Red Herring to see past the "buzz" and make the list a valuable instrument for discovering and advocating the greatest business opportunities in the industry. Endobetix offers remission of type 2 diabetes with a simple, effective solution. The minimally invasive, nonsurgical implant for the treatment of type 2 diabetes and obesity developed by Endobetix mimics the hormonal benefits offered by bariatric surgery. For many patients with diabetes, surgery is not an option and combination oral therapy is inadequate. The Endobetix implant provides a much safer and significantly less costly option than current solutions. Chen Porat, CEO of Endobetix, remarked, "We are very excited about our selection as a finalist for this award. As an out-of-the box treatment for diabetes - a disease that has reached epidemic proportions - Endobetix indeed fulfills the criteria of the competition. We are confident that our product will bring about a significant improvement in the treatment of type 2 diabetes and obesity. " "This year was rewarding, beyond all expectations," said Alex Vieux, publisher and CEO of Red Herring. "There are many great companies producing really innovative and amazing products in Europe. We had a very difficult time narrowing the pool and selecting the finalists. Endobetix shows great promise and therefore deserves to be among the Finalists. Now we're faced with the difficult task of selecting the Top 100 winners of Red Herring Europe. We know that the 2015 crop will grow into some amazing companies that are sure to make an impact. " Finalists for the 2015 edition of the Red Herring 100 Europe award are selected based upon their technological innovation, management strength, market size, investor record, customer acquisition, and financial health. During the months leading up to the announcement, hundreds of companies in the telecommunications, security, Web 2.0, software, hardware, biotech, mobile and other industries completed their submissions to qualify for the award. The Trendlines Group is an innovation commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfill its mission to improve the human condition. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Media relations:

  • Where is Endobetix's headquarters?

    Endobetix's headquarters is located at 17 Tchelet Street, Misgav.

  • What is Endobetix's latest funding round?

    Endobetix's latest funding round is Other Investors.

  • Who are the investors of Endobetix?

    Investors of Endobetix include The Trendlines Group.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.